CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced results from two indirect treatment comparison (ITC) analyses presented at the 2026 American Urological Association (AUA) Annual Meeting evaluating nogapendekin alfa inbakicept-pmln (NAI, ANKTIVA®) plus Bacillus Calmette–Guérin (BCG) against two other U.S. Food and Drug…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
